In brief
A company's funded proposal to refine and clinically test a wearable acoustic monitor that scores the risk of opioid-induced respiratory depression; it describes aims and design, not proven results.
What this article is about
Quick Answer
A company's funded proposal to refine and clinically test a wearable acoustic monitor that scores the risk of opioid-induced respiratory depression; it describes aims and design, not proven results.
Student takeaways
Key Takeaways
- This is a funded device-development proposal (SBIR); it reports aims, design, and background, not clinical results, and feasibility is claimed but accuracy and benefit are unproven.
- As background, opioids are the most prescribed hospital drugs and opioid-induced respiratory depression (OIRD) occurs in up to 46% of patients on general floors.
- The proposed Respiratory Monitoring System uses an acoustic Trachea Sound Sensor plus software to continuously measure many respiratory and vital signs and computes a Risk Index Score for OIRD every 20 seconds.
- The device has FDA Breakthrough Device Designation, which speeds development but does not by itself prove efficacy or safety.
- Development is staged: Phase 1 optimises noise handling and tests measurement accuracy; Phase 2 builds the device and plans an observational trial in 120 post-operative opioid patients.
Student summary
Why This Research Matters
This is a funded product-development proposal supported by the National Institute on Drug Abuse. It comes from a company, RTM Vital Signs, LLC, and describes plans to optimise and test a wearable device. It is not a completed clinical trial, so it reports goals, design, and background context rather than clinical results. Any statistics below are background or planned study features, not outcomes of this project. An important clarification comes first, especially for a mental-health library: the 'depression' in this project means respiratory depression, that is, dangerously slowed or shallow breathing, not depression as a mood disorder. The two are unrelated here. The clinical problem is opioid-induced respiratory depression (OIRD). Opioids are described as the most prescribed drugs in U.S. hospitals, and OIRD, when opioids suppress breathing, is a common and life-threatening complication. The proposal states that OIRD episodes on general hospital floors are common, occurring in up to 46 percent of patients. The danger is that OIRD can progress to severe hypoventilation, low blood oxygen (hypoxemia), abnormal heart rhythms, and death. The authors argue that current monitoring has not solved this problem, in part because comprehensive methods like continuous pulse oximetry combined with capnography are impractical to apply to every patient on a general floor. The proposed solution is a wearable, wireless Respiratory Monitoring System (RMS). It uses an acoustic Trachea Sound Sensor (TSS), a sensor that listens to breathing sounds at the throat, together with a software algorithm. The system is designed to measure many signals continuously, including respiratory rate, tidal volume (the size of each breath), minute ventilation, breathing pattern, the length of any pauses in breathing (apnea), oxygen saturation, snoring, heart rate, body position, and activity. From these, the algorithm calculates a Risk Index Score for OIRD every 20 seconds, with the goal of giving actionable alerts before a patient becomes critically ill. The device has received Breakthrough Device Designation from the U.S. Food and Drug Administration, a status meant to speed development of promising devices for serious conditions. The proposal lays out staged development. In Phase 1, the team plans to improve the device's software with dynamic filtering and active noise cancellation so it works in noisy hospital settings (Aim 1), then run a human study to measure how accurately it captures respiratory rate, tidal volume, and apnea duration with the noise-handling software turned on versus off (Aim 2). In Phase 2, they plan to build and bench-test the finished device (Aim 1), then obtain an FDA Investigational Device Exemption and conduct an observational clinical trial in 120 post-operative surgical patients receiving fentanyl and other opioids, to see whether the device can detect and predict OIRD events (Aim 2). For nursing students, this proposal connects to core safety practice. Nurses are central to monitoring patients on opioids, recognising early signs of respiratory depression such as a slowed breathing rate, increasing sedation, and falling oxygen levels, and responding quickly. It also illustrates the promise and the limits of technology: a good monitor can support, but not replace, careful nursing assessment and clinical judgment. Several cautions are essential. Because this is a development proposal, there is no evidence here that the device accurately detects or prevents OIRD in real patients; that is exactly what the planned studies aim to test. Feasibility has been demonstrated, but accuracy and clinical benefit are not yet established. Breakthrough Device Designation supports faster development but is not proof that a device works or is safe. Finally, no monitoring device removes the need for cautious opioid dosing, appropriate patient selection, and vigilant bedside assessment; alarms and scores are aids, not substitutes, for the nurse. In summary, this proposal describes a wearable acoustic monitor intended to catch opioid-induced breathing problems early, along with a staged plan to refine and clinically test it. Its value lies in the clinical need it targets and the study design it proposes; whether the device reliably detects and predicts OIRD remains to be shown.
Source abstract
Study Overview
PROJECT SUMMARY. Opioids are the most prescribed drug in US hospitals, and opioid induced respiratory depression (OIRD) is a widespread and life-threatening problem. Episodes of OIRD on the general hospital floor are common, occurring in up to 46% of patients. Despite the prevalence of this problem, OIRD has yet to be effectively addressed through monitoring technology. There is great clinical need for a wearable sensor capable of detecting the onset and progression of OIRD with actionable alerts, well before the onset of severe hypoventilation, hypoxemia, cardiac arrhythmia, and death. To meet this clinical need, RTM Vital Signs, LLC is developing a wearable, wireless Respiratory Monitoring System (RMS) with an acoustic Trachea Sound Sensor (TSS) and a software algorithm that continuously measures a person’s respiratory rate (RR), tidal volume (TV), minute ventilation (MV), breathing pattern, duration of apnea, oxygen saturation, degree of snoring, heart rate (HR), body position, and activity level. The RMS algorithm calculates a Risk Index Score (RIS) specifically for OIRD every 20 seconds. RTM has received Breakthrough Device Designation from the FDA to develop the RMS for the prevention of an opioid overdose and death in hospitalized patients, outpatients, and US citizens that chronically use or abuse opioids. RTM plans to commercialize the RMS first for monitoring hospitalized patients managed with opioids on the general nursing floors, due to the high incidence of OIRD in these environments and the impracticality of using existing methods such as pulse oximetry combined with capnography to provide sufficient monitoring for all patients receiving opioids. Having already demonstrated feasibility of our technology, we are working to optimize the RMS to handle noisy environments and validate the system in a clinical study. In Phase 1, we will optimize the existing RMS with dynamic filtering and active noise cancellation software (Phase 1, Aim 1) and conduct a human study using the optimized RMS to measure the accuracy of RR, TV, and apnea duration in a noisy environment with the filtering/noise cancellation software turned on, versus turned off (Phase 1, Aim 2). In Phase 2, we will construct and bench-test functional RMS prior to a human clinical trial (Phase 2, Aim 1), obtain an FDA Investigational Device Exemption (IDE), and then conduct an observational clinical trial in post-operative surgical patients managed with fentanyl and other opioids to demonstrate RMS’s ability to detect and predict the onset and progression of an OIRD event (n = 120 patients) (Phase 2, Aim 2). Together, these steps will accomplish key development milestones and clinical testing needed for regulatory approval and commercialization of the RMS device. Successful completion of this project will produce a commercially viable wearable wireless RMS with the potential to improve the health and safety of patients receiving opioids by accurately detecting and predicting OIRD with actionable alerts prior to the onset of severe hypoventilation, hypoxemia, cardiac arrhythmia, and death.
Evidence appraisal
Main Findings
- This is a funded device-development proposal (SBIR); it reports aims, design, and background, not clinical results, and feasibility is claimed but accuracy and benefit are unproven.
- As background, opioids are the most prescribed hospital drugs and opioid-induced respiratory depression (OIRD) occurs in up to 46% of patients on general floors.
- The proposed Respiratory Monitoring System uses an acoustic Trachea Sound Sensor plus software to continuously measure many respiratory and vital signs and computes a Risk Index Score for OIRD every 20 seconds.
- The device has FDA Breakthrough Device Designation, which speeds development but does not by itself prove efficacy or safety.
- Development is staged: Phase 1 optimises noise handling and tests measurement accuracy; Phase 2 builds the device and plans an observational trial in 120 post-operative opioid patients.
Practice transfer
Clinical Relevance
- Nurses remain central to opioid safety, monitoring respiratory rate, sedation level, and oxygenation, and responding early to signs of respiratory depression.
- Continuous monitoring may help on general floors where OIRD is common and comprehensive monitoring of every patient is impractical, but its value here is not yet proven.
- Any risk score or alarm is a decision aid; it does not replace bedside assessment or safe opioid dosing and patient selection.
- Clarify with patients and teams that 'respiratory depression' means suppressed breathing, distinct from mood-related depression.
- Awareness of alarm fatigue and over-reliance on technology is important when adopting new monitoring devices.
Faculty notes
Educational Relevance
This NIDA-funded SBIR proposal is useful for teaching patient safety, opioid stewardship, and critical appraisal of medical devices. Clarify immediately that 'depression' here means respiratory depression, not a mood disorder, an instructive lesson in reading past keyword tags. Emphasise the document is a development plan: feasibility is claimed, but detection accuracy and clinical benefit are unproven, and FDA Breakthrough Device Designation accelerates review without demonstrating efficacy. Use the wearable Respiratory Monitoring System, with its acoustic trachea sound sensor and 20-second Risk Index Score, to discuss what continuous monitoring can and cannot add on general nursing floors, and why universal pulse-oximetry-plus-capnography is impractical. Connect to nursing fundamentals: recognising early OIRD (declining respiratory rate, increasing sedation, hypoxemia), the sedation-precedes-hypoxia sequence, and the limits of pulse oximetry in patients on supplemental oxygen. The staged Phase 1 and Phase 2 aims (noise-handling optimisation, accuracy testing, then an n=120 observational post-operative trial) let you teach device-development pathways and evidence hierarchies. A strong critique prompt: what would convince you the Risk Index Score is clinically actionable, and what are the risks of alarm fatigue and over-reliance on technology at the bedside?
Critical appraisal
Limitations
- As a development proposal, the source provides no clinical outcomes; whether the device accurately detects or predicts OIRD is untested here.
- The planned validation trial is observational and modest (n=120 post-operative patients), which limits the strength of eventual conclusions.
- The project is company-sponsored, and FDA Breakthrough Designation does not equal proof of effectiveness or safety.
Classroom use
Discussion Questions
- What is opioid-induced respiratory depression, and why is it dangerous?
- Why is respiratory depression different from depression as a mood disorder, and why might confusing them matter?
- What are the early warning signs of respiratory depression that nurses monitor for?
- Why is continuous pulse oximetry plus capnography impractical for every patient on a general floor?
- What are the potential benefits and risks of adding a wearable risk-score monitor at the bedside?
- What does FDA Breakthrough Device Designation actually mean, and what does it not prove?
- Why does feasibility of a device not guarantee clinical accuracy or benefit?
- How could alarm fatigue undermine the value of a new monitoring system?
- What are the strengths and limits of an observational trial with 120 patients for evaluating a safety device?
- How should nurses balance trust in monitoring technology with their own clinical assessment?
Search-ready answers
Frequently asked questions
Does this device prevent opioid overdoses?
Not proven. It is in development; the studies aim to test whether it can detect and predict respiratory depression.
Is this about mental-health depression?
No. It concerns respiratory depression, dangerously slowed or shallow breathing from opioids.
What is opioid-induced respiratory depression?
When opioids suppress the drive to breathe, reducing breathing rate and depth and lowering oxygen.
How does the device work?
An acoustic sensor at the throat plus software track breathing and vital signs and compute a risk score every 20 seconds.
What does FDA Breakthrough Device Designation mean?
It speeds development and review of promising devices for serious conditions; it is not proof the device works.
Why monitor patients on general floors?
OIRD is common there and it is impractical to give every patient comprehensive monitoring like capnography.
Can the device replace the nurse?
No. It is a decision aid; safe opioid dosing and bedside assessment remain essential.
How large is the planned clinical trial?
An observational study of 120 post-operative patients receiving opioids.
What early signs of respiratory depression should nurses watch for?
Slowing respiratory rate, increasing sedation, and falling oxygen saturation.
Is the device proven accurate?
Not yet. Feasibility is claimed, but accuracy and clinical benefit are what the planned studies must establish.